The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
Tislelizumab is now approved for seven indications in China
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The medicine is now approved for eight indications across five different types of cancer in China.
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
Subscribe To Our Newsletter & Stay Updated
